NxStage Medical (NSDQ:NXTM) today released data from a study comparing home hemodialysis to traditional treatment in a skilled nursing facility, touting a lower risk of death and cardiovascular hospitalization for those treated more often with home hemodialysis.
Full results from the trial are slated to be presented at the American Society of Nephrology Kidney Week 2018 Annual Meeting next week, the Lawrence, Mass.-based company said.
Investigators analyzed data collected from 3,619 patients treated in skilled nursing facilities between 2011 and 2015, and found that patients treated more frequently at home experienced a 34% lower risk of death and 23% lower risk of cardiovascular hospitalization compared to those receiving conventional hemodialysis in an SNF setting.
“Because patients undergoing dialysis have a high burden of cardiovascular disease, a 23% reduction in cardiovascular-related hospitalization is very clinically meaningful. These findings are even more impressive in the high-risk population of patients who reside in skilled nursing facilities,” Dr. Maria Rosa Costanzo of the Advocate Heart Institute said in a prepared statement.
“The significant survival and cardiovascular benefits associated with more frequent on-site home hemodialysis provides confidence and clear support for a new standard of care for dialysis patients within skilled nursing facilities. Home hemodialysis provided in the skilled nursing facility setting eliminates the needs and risks of high-cost and disruptive transportation to and from dialysis clinics, and by reducing hospitalization, more frequent on-site home hemodialysis can provide better patient health outcomes at a lower cost of care,” NxStage Medical chief medical officer said in a press release.
In late July, Fresenius (NYSE:FMS) said that it extended the deadline to close the $2 billion buyout of NxStage Medical by 90 days, pushing the deadline from August 7 to November 5.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.